Theraclion FY26 H1 net loss widens 42% to €3.61 million; revenue falls 21% to €663,000

• Theraclion posted H1 revenue of €663,000, down 21%, while operating loss widened 36% to €3.92 million.
• Net loss widened 42% to €3.61 million; PPU and consumables sales rose 9% to €333,000.
• Service sales fell 86% to €34,000; the drop was largely explained by the expiration of legacy multi-year contracts.
• Cash totaled €5.2 million at June 30, 2026, with runway extending into Q1 or Q2 2027; FDA De Novo decision expected late Q3 or early Q4.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theraclion SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260916569081) on September 16, 2026, and is solely responsible for the information contained therein.